Search
Citations et références (17)
Gibco™
StemPro™-34 SFM (1X)
StemPro-34 SFM est un milieu exempt de sérum spécialement formulé pour favoriser la croissance des cellules hématopoïétiques humaines en culture,Afficher plus
| Référence | Quantité |
|---|---|
| 10639011 | 500 ml |
Référence 10639011
Prix (EUR)
352,65
Online Exclusive
392,00Économisez 39,35 (10%)
Each
Quantité:
500 ml
Prix (EUR)
352,65
Online Exclusive
392,00Économisez 39,35 (10%)
Each
StemPro-34 SFM est un milieu exempt de sérum spécialement formulé pour favoriser la croissance des cellules hématopoïétiques humaines en culture, y compris les CSH et les cellules progénitrices isolées à partir de moelle osseuse, de sang de cordon ombilical et de sang périphérique. StemPro-34 SFM est un milieu de culture cellulaire flexible qui peut être utilisé pour une grande variété d’applications.
Pour les applications traitant de culture cellulaire et tissulaire ex vivo. MISE EN GARDE : Lorsqu’il est utilisé comme dispositif médical, la Loi fédérale impose que ce dispositif ne soit vendu que sur prescription d’un médecin.
Spécifications
Type de celluleCellule souche hématopoïétique, cellule hématopoïétique, moelle osseuse
Niveau d’endotoxines≤ 10 UE/mL
Gamme de produitsStemPro
Type de produitMilieux sans sérum de cellules souches (SFM)
Quantité500 ml
EspècesHumaine
ClassificationSans sérum
Culture Typeculture en suspension stationnaire
FormeLiquide
Serum LevelSans sérum
Avec additifsRouge de phénol
Sans additifSans glutamine
Unit SizeEach
Contenu et stockage
• Milieu sans sérum StemPro™-34 de 500 ml (stocker entre 2°C et 8°C dans l’obscurité)
• 13 ml de supplément de nutriments StemPro™-34 (stocker entre -5°C et -20°C dans l’obscurité)
Stocker le milieu complet entre 2°C et 8°C dans l’obscurité.
• 13 ml de supplément de nutriments StemPro™-34 (stocker entre -5°C et -20°C dans l’obscurité)
Stocker le milieu complet entre 2°C et 8°C dans l’obscurité.
Citations et références (17)
Citations et références
Abstract
Functional profiling of single CRISPR/Cas9-edited human long-term hematopoietic stem cells.
Journal:Nature communications
PubMed ID:31628330
In the human hematopoietic system, rare self-renewing multipotent long-term hematopoietic stem cells (LT-HSCs) are responsible for the lifelong production of mature blood cells and are the rational target for clinical regenerative therapies. However, the heterogeneity in the hematopoietic stem cell compartment and variable outcomes of CRISPR/Cas9 editing make functional interrogation
Ex vivo expanded human cord blood-derived hematopoietic progenitor cells induce lung growth and alveolarization in injured newborn lungs.
Journal:Respiratory research
PubMed ID:23522153
BACKGROUND: We investigated the capacity of expanded cord blood-derived CD34+ hematopoietic progenitor cells to undergo respiratory epithelial differentiation ex vivo, and to engraft and attenuate alveolar disruption in injured newborn murine lungs in vivo. METHODS: Respiratory epithelial differentiation was studied in CD34+ cells expanded in the presence of growth factors
Human pluripotent stem cells differentiated in fully defined medium generate hematopoietic CD34- and CD34+ progenitors with distinct characteristics.
Journal:PloS one
PubMed ID:21364915
BACKGROUND: Differentiation of pluripotent stem cells in vitro provides a powerful means to investigate early developmental fates, including hematopoiesis. In particular, the use of a fully defined medium (FDM) would avoid biases induced by unidentified factors contained in serum, and would also allow key molecular mediators involved in such a
Development of the hemangioblast defines the onset of hematopoiesis in human ES cell differentiation cultures.
Journal:Blood
PubMed ID:17148580
The onset of hematopoiesis in the mouse embryo and in the embryonic stem (ES) cell differentiation model is defined by the emergence of the hemangioblast, a progenitor with both hematopoietic and vascular potential. While there is evidence for the existence of a hemangioblast in the mouse, it is unclear if
Differentiation of Human-Induced Pluripotent Stem Cells to Macrophages for Disease Modeling and Functional Genomics.
Journal:Current protocols in stem cell biology
PubMed ID:30537374
Macrophages play important roles in many diseases. We describe a protocol and the associated resources for the differentiation of human induced pluripotent stem cell-derived macrophages (IPSDM) and their applications in understanding human macrophage physiology and relevant diseases. The protocol uses an embryoid bodyâbased approach with a combination of serum-free condition